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Abstract
Pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (pj) can lead to serious health 
consequences in patients with an immunocompromised system. Trimethoprim (TMP), used as 
first-line therapy in combination with sulfamethoxazole, is a selective but only moderately potent 
pj dihydrofolate reductase (pjDHFR) inhibitor, whereas non-clinical pjDHFR inhibitors, such as, 
piritrexim and trimetrexate are potent but non-selective pjDHFR inhibitors. To meet the clinical 
needs for a potent and selective pjDHFR inhibitor for PCP treatment, fourteen 6-substituted 
pyrido[3,2-d]pyrimidines were developed. Comparison of the amino acid residues in the active site 
of pjDHFR and human DHFR (hDHFR) revealed prominent amino acid differences which could 
be exploited to structurally design potent and selective pjDHFR inhibitors. Molecular modeling 
followed by enzyme assays of the compounds revealed 15 as the best compound of the series with 
an IC50 of 80 nM and 28-fold selectivity for inhibiting pjDHFR over hDHFR. Compound 15 
serves as the lead analog for further structural variations to afford more potent and selective 
pjDHFR inhibitors.
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Pneumocystis carinii pneumonia (PCP) caused by Pneumocystis jirovecii is a fungal 
infection which affects patients with altered host immunity, such as, patients with cancer, 
transplant recipients, patients with HIV/AIDS and patients on immunosuppressive 
medications. [1–6] In HIV patients, PCP leads to pulmonary inflammation, hospitalization, 
and death.[7–10] If left untreated, PCP is almost always fatal. Even when treated, the 
mortality rate is 10%.[11] In the USA, 9% of HIV infected patients and 1% of organ 
transplant recipients develop PCP infection.[12] Although PCP prophylaxis and highly 
active antiretroviral therapy (HAART) in AIDS has decreased the incidences of PCP 
infection, cases still persist due to non-adherence to HIV medication, toxicity to the HIV 
medications, emergence of drug resistant HIV strains, late diagnosis of HIV and the rise of 
the number of HIV cases in developing countries along with resistance to currently used 
drugs for PCP.[13, 14]
For past few decades, oral administration of trimethoprim (TMP)-sulfamethoxazole (SMX) 
combination (co-trimoxazole) has been the first line choice for both prophylaxis and 
treatment of PCP.[15, 16] The combination synergistically blocks folic acid synthesis, since 
TMP (Figure 1) is a selective, but weak inhibitor of dihydrofolate reductase (DHFR)[17], 
while SMX is an inhibitor of dihydropteroate synthase (DHPS).[18] The low activity of 
TMP against DHFR is augmented by SMX in the treatment regimen. This combination is 
less well tolerated in patients with HIV/AIDS, where 50–80% experience side-effects due to 
SMX. The most common one being a diffuse maculopapular rash, sometimes accompanied 
with fever which often leads to discontinuation of treatment.[19, 20] The alternative therapy 
can be (i) pentamidine (intravenous - infused over an hour); (ii) TMP-dapsone (oral); or (iii) 
clindamycin (intravenous) – primaquine (oral), which are not preferred due to higher 
prevalence of side-effects and in some cases lower efficacy.[15, 21–24] Experimental drugs 
such as piritrexim (PTX) and trimetrexate (TMQ) (Fig. 1) are potent, but non-selective 
inhibitors of DHFR, which cause dose-limiting toxicities.[15, 25, 26] Thus, for patients who 
do not respond to first line treatment, development of effective and safe drugs for the 
treatment of PCP is critically warranted. Our long-term goal is to provide analogs with 
excellent potency along with high selectivity for Pneumocystis jirovecii DHFR (pjDHFR) 
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over human DHFR (hDHFR). Such agents could be used alone as well as in combination 
with sulfonamides and other drugs for PCP infections in humans.
Although it has been widely known that PCP is a host specific infection, drugs designed for 
PCP have been evaluated against Pneumocystis carinii DHFR (pcDHFR), and not pjDHFR.
[17, 27] Pneumocystis carinii (pc), the causative species in rats is different from 
Pneumocystis jirovecii responsible for human infections. There is a 38% difference in the 
amino acid sequence of pcDHFR and pjDHFR which suggests that drugs evaluated against 
the surrogate pcDHFR in vitro or in vivo, may not translate to the treatment of PCP infection 
in humans.[28, 29] In the absence of crystal structure information for pjDHFR, a tissue 
culture or a PCP animal model for in vitro studies for PCP cause severe impediments in drug 
discovery efforts. In fact, since the preliminary evaluation of TMP/SMX there has been no 
new treatment for PCP caused by P. jirovecii that could effectively supplant TMP/SMX.
Gangjee and coworkers[28] reported pyrido[2,3-d]pyrimidines 1–6 as somewhat selective 
and potent pjDHFR inhibitors (Table 1).
To compare the binding of 1 in the active sites of pjDHFR and hDHFR, a docking study of 1 
was performed using the refined reported homology model of pjDHFR [32] and the crystal 
structure of hDHFR in Schrödinger.[31] In pjDHFR, the pyrido[2,3-d]pyrimidine scaffold is 
stabilized by a π-π stacking interaction with Phe36. The protonated N1 and 2-NH2 of 1 
form an ionic bond with Asp32 in the form of a salt bridge. The 4-NH2 forms hydrogen 
bonding interaction with the backbone carbonyl of Ile10. The side chain phenyl ring is 
oriented in a pocket formed by Leu25, Met33, Ser64, and Leu65. The N9-H group is 
oriented towards the Ile123 side chain. In hDHFR, the pyrido[2,3-d]pyrimidine scaffold is 
also stabilized by a π-π stacking interaction with Phe34. The protonated N1 and 2-NH2 
form an ionic bond with Glu30. The 4-NH2 forms hydrogen bonding interaction between the 
backbone carbonyl of Ile7. The side chain phenyl ring is oriented in a pocket formed by 
Leu22, Phe31, Ser59, and Ile60. The N9-H group is oriented towards the Val115 side chain. 
The docking scores of 1 in the pjDHFR homology model and hDHFR crystal structure were 
−7.88 kcal/mol and −9.54 kcal/mol, respectively. The in vitro IC50 values of 1 reflect the 
docking scores obtained with the inhibition of hDHFR somewhat better than that for 
pjDHFR for 1 (Table 1). This provides validation of our docking protocol in the homology 
model of pjDHFR compared with docking in hDHFR crystal structure.
The amino acids that constitute the active site of pjDHFR and hDHFR, as visible from 
Figure 2, are quite distinct. The hDHFR active site contains Phe31, Ile60, and Val115, 
whereas active site of pjDHFR contains Met33, Leu65, and Ile123. The different amino 
acids occupying the same location in the active sites, such as Met33 (in pjDHFR) vs. Phe31 
(in hDHFR) and Ile 123 (in pjDHFR) vs. Val115 (in hDHFR), possess varied shapes, sizes 
and electronic properties. Such differences can be exploited for the design of inhibitors to 
provide potency and selectivity for pjDHFR over hDHFR. We reported our efforts in 
targeting the amino acid difference of Met33 (in pjDHFR) and Phe31 (in hDHFR) by 
varying substitutions on the 7-position of a truncated pyrrolo[2,3-d]pyrimidine scaffold.[32] 
The 6-subtituted pyridopyrimidines evaluated thus far against pjDHFR consist of the 
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pyrido[2,3-d]pyrmidine scaffold. No study of significant variation of the scaffold has been 
carried out to our knowledge.
Gangjee et al.[34] reported the pyrido[2,3-d]pyrimidines and their analogs as inhibitors of 
pcDHFR. Rosowsky et al.[33] synthesized and evaluated the regioisomeric pyrido[3,2-
d]pyrimidine analogs as inhibitors of pcDHFR. The biological evaluation of pyrido[3,2-
d]pyrimidine 7 (Table 2) in pcDHFR and rat liver DHFR (rlDHFR) displayed a 5-fold 
increase in potency for pcDHFR, compared to its regio pyrido[2,3-d]pyrimidine analog 8 
(Table 2). This comparison suggested that scaffold replacement of a pyrido[2,3-d]pyrimidine 
to a pyrido[3,2-d]pyrimidine improved the potency for pcDHFR and a similar approach 
could perhaps be useful to improve the potency for pjDHFR. Gangjee at al. [33] also 
reported 6-substituted pyrido[3,2-d]pyrimidines as inhibitors of pcDHFR. However because 
of the amino acid differences, as reported in Shah et al.,[31] it has been validated that 
activity against pcDHFR does not translate into activity against pjDHFR. Hence, it was 
important to synthesize and evaluate the pyrido[3,2-d]pyrimidine series of compounds as 
selective pjDHFR inhibitors, (Fig. 3).
To study the probable binding modes of compounds obtained via a scaffold hopping of 
pyrido[2,3-d]pyrimidine with pyrido[3,2-d]pyrimidine, 9 (Fig. 3) was docked in the active 
sites of pjDHFR and hDHFR using the reported homology model of pjDHFR and crystal 
structure of hDHFR, with Schrödinger.[28, 30] (Fig. 4). The pyrido[3,2-d]pyrimidine 9 
exhibited a similar docked pose as 1 suggesting the scaffold binding could be at least as 
favorable as the pyrido[2,3-d]pyrimidine scaffold. The docking scores of 9 in the pjDHFR 
homology model and hDHFR crystal structure were −8.22 kcal/mol and −8.87 kcal/mol, 
respectively. Compared to the docking score of 1 in the pjDHFR homology model (−7.88 
kcal/mol), 9 displayed a higher binding potential to pjDHFR, whereas compared to the 
docking score of 1 in hDHFR crystal structure (−9.54 kcal/mol), 9 displayed a lower binding 
potential to hDHFR. This suggested that a scaffold change from pyrido[2,3-d]pyrimidine to 
pyrido[3,2-d]pyrimidine could afford increased potency and selectivity for pjDHFR.
The reported pyrido[2,3-d]pyrimidine compounds 1–6 (Table 1) displayed moderate 
potencies for pjDHFR, but none were significantly selective for pjDHFR over hDHFR. 
Compounds 9–17 (Figure 3), were designed as pyrido[3,2-d]pyrimidine analogs of 1–6. The 
shape of the pjDHFR active site and hDHFR active site differ due to presence of Met33 
(flexible residue) and Leu65 in pjDHFR and Phe31 (bulkier residue) and Ile60 in hDHFR. 
Compounds 9–12 (Fig. 3) were designed as analogs of 1–3 (Table 1) to determine the 
influence of the pyrido[3,2-d]pyrimidine system and the electron donating substitutions on 
the side chain aryl group on activity against pjDHFR and hDHFR. These compounds were 
anticipated to provide a structure activity relationship through electron donating groups 
(inductive and resonance). Compounds 13 and 14 (Table 3) were designed as pyrido[3,2-
d]pyrimidine analogs of 4 and 5 (Table 1). Due to the bulkier size of the naphthyl group, the 
side chains of these proposed compounds were expected to sterically clash with the side 
chain Phe31 in hDHFR. This clash is absent in pjDHFR, since the pjDHFR active site is 
composed of a flexible Met33 residue instead of Phe31 (in hDHFR) at this position. 
Compounds 15–17 (Table 3) were designed as analogs of 6 (Table 1). These compounds 
contain electron withdrawing groups to evaluate their influence on DHFR inhibitory activity.
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As observed from the docking of 9 and 18 in Figure 5, the N-CH3 of 18 is oriented towards 
the Ile123 side chain in the pjDHFR active site. An appropriate alkyl substitution on the 
nitrogen lead to compounds that can interact with the longer Ile123 (in pjDHFR) and not 
with shorter Val115 (in hDHFR). Hence, the N-CH3 analog 18 would be expected to afford 
an improvement in pjDHFR potency and selectivity over hDHFR. Docking of 18 in the 
active site of pjDHFR using the reported homology model of pjDHFR and superimposition 
of the docked pose of 18 in the active site of pjDHFR over the docked pose of 9 in the active 
site of pjDHFR is shown in Figure 5a. The docking study revealed that both compounds 
display a bidentate ionic bond between the protonated N1 and the 2-NH2 with Asp32. The 4-
NH2 moiety for both 9 and 18 forms hydrogen bonds with the backbone of Ile10 and the 
pyrrolo[3,2-d]pyrimidine scaffold is stabilized by π-π-stacking interaction with Phe36. The 
phenyl moiety is oriented in the pocket formed by Leu25, Met33, Ser64 and Leu65. The 
distance between Ile123 side chain and the N9-of the pyrido[3,2-d]pyrimidine 9 was 4.47 Å, 
whereas the distance between the Ile123 side chain and N9-methyl group of the pyrido[3,2-
d]pyrimidine 18 was 3.43 Å. Since all other interactions are similar for 9 and 18, the 
additional N9-CH3 on 18 can potentially have stronger hydrophobic interactions with 
pjDHFR, than 9. The best docked poses for 9 and 18 in the pjDHFR homology model 
generated docking scores of −8.22 kcal/mol and −8.02 kcal/mol, respectively. Figure 5b 
displays the best docked conformation of 9 and 18 in hDHFR crystal structure (PDB: 4QJC, 
1.61 Å).[30] The analogs exhibit a bidentate ionic interaction of the protonated N1 and 2-
NH2 with Glu30. The 4-NH2 hydrogen bonds with the backbone of Ile7. The phenyl moiety 
is oriented in the pocket formed by Leu22, Phe31 and Ser59. The scaffold is stabilized by π-
π-stacking interactions with Phe34. The distance between Val115 side chain and nitrogen 
substituted at the 6-position of the pyrido[3,2-d]pyrimidine 9 was 5.83 Å, whereas the 
distance between Val115 side chain and N9-CH3 of the pyrido[3,2-d]pyrimidine 18 as 4.36 
Å. The best docked poses for 9 and 18 in hDHFR crystal structure generated docking scores 
of −8.87 kcal/mol and −9.39 kcal/mol, respectively. To further evaluate the optimum length 
of the alkyl moiety required to interact with Ile123 (in pjDHFR) and not the shorter Val115 
(in hDHFR), longer and branched chain alkyl groups were designed for evaluation for 
substitution at the N9-position. Thus, it was of interest to synthesize N9-alkyl pyrido[3,2-
d]pyrimidines 18–22. All the proposed compounds 9–22 displayed better docking scores for 
pjDHFR over hDHFR, compared to the lead compound 1 (docking scores are included in the 
supporting information) indicating possible increase in potency and selectivity for pjDHFR 
over hDHFR.
Intermediate 25 (Scheme 1) was synthesized following a reported procedure.[35, 36] The 
2,6-dichloropyridine 23 was nitrated with 90% nitric acid and sulfuric acid, followed by 
substitution of the 2-Cl moiety with cuprous cyanide at 180 °C to afford 2-cyano-3-nitro-6-
chloropyridine 25. The structure of 25 was confirmed from the coupling constants (J) of the 
protons [1H-NMR (400 Hz) δ 7.80 (d, J = 7.2 Hz, 1 H), 8.58 (d, J = 7.2 Hz, 1 H)]. The 
coupling constants match the characteristic J constants for ortho coupling between aromatic 
protons.[37]
Following the reported procedure,[38] synthesis of 26 (Scheme 1) was attempted. 
Compound 25 was reacted with the 3,4,5-trifluoroaniline in monoethylglycol in the presence 
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of pyridine at 140 °C. The reaction did not yield any product after 12 h. The reason for the 
failure of the reaction could be the poor nucleophilicity of the 3,4,5-trifluoroaniline.
In order to carry out the displacement with a weak nucleophile such as 3,4,5-trifluoroaniline 
on 25, the alternate methodology reported by Gangjee et al.[38] was followed (Scheme 2). 
The 3,4,5-trifluoroaniline was first treated with LDA at −78 °C to afford a more reactive 
nitrogen anion, followed by displacement of the 6-chloro group of 25 to afford 26 in 10% 
yield.
The syntheses of 9–22 were accomplished from 25 as shown in Scheme 2. To a solution of 
6-chloro-3-nitro-2-pyridinecarbonitrile (25) in isopropanol, the appropriate aniline was 
added and the mixture was heated at 130 °C (Scheme 1). After 3–16 h, the solution was 
concentrated under reduced pressure to afford 26–38. This step using isopropanol afforded 
increased yields and provided safer conditions, compared to the displacement using LDA. 
The mixture was not separated and was advanced to the next step. The nitro compounds 26–
38 were reduced using iron powder in concentrated hydrochloric acid to afford 39–52.[38] 
The formation of the amino compounds 39–52 is indicated by a blue fluorescence on TLC at 
254 nm. These amino compounds 39–52 were not separated and advanced to the cyclization 
step. During the reduction of 29 to 41 (R2= 4-OCH3), the methoxy group undergoes partial 
ether cleavage in the work up step and afforded two very close spots on the TLC (possibly 
for 41 and 42). To obtain the target compounds, the reported method[38] was followed for 
the cyclization of 39–52 in dimethyl sulfone at 140 °C to afford 9–22.
Table 3 displays the IC50 values of compounds 9–22 for pjDHFR and hDHFR. Comparison 
of activities of pyrido[3,2-d]pyrimidines vs. pyrido[2,3-d]pyrimidines for pjDHFR, hDHFR 
and selectivity ratios, indicates that the scaffold replacement strategy was favorable. 
Biological evaluation of 9 against pjDHFR and hDHFR displayed an improvement of greater 
than 2-fold in pjDHFR potency, compared to its regio isomer 1 (Table 3).[28] Additionally, 
the selectivity for pjDHFR over hDHFR for 9 also improved significantly (>13-fold), 
compared to 1.
As observed for pyrido[3,2-d]pyrimidine 9, a considerable improvement in selectivity was 
seen for compounds 10 (vs. 2), 11 (vs. 3), 13 (vs. 4), 14 (vs. 5), and 15 and 16 (vs. 6), 
validating the rationale of the scaffold hopping strategy. The trifluoro-substituted analog 15 
showed the highest selectivity for pjDHFR over hDHFR in the series, which is 560-fold 
greater than the selectivity ratio of PTX. Compared to its pyrido[2,3-d]pyrimidine analog 6, 
15 showed an 11-fold improvement in the potency towards pjDHFR and a 7-fold 
improvement in the selectivity ratio for pjDHFR over hDHFR. The improved potency and 
selectivity of 15 for pjDHFR could be due to a better binding of 15 with the active site of 
pjDHFR compared to that of other ligands.
The alkyl analogs 18–22 in the N9-substituted pyrido[3,2-d]pyrimidine-2,4,6-triamines were 
designed to obtain better hydrophobic interactions with Ile123 (in pjDHFR) vs. Val115 (in 
hDHFR). The N9-alkyl analogs 18–21 did not show a significant improvement in pjDHFR 
potency and selectivity, compared to the N9-H analog 9. The absence of improvement in 
potency and/or selectivity for pjDHFR could be due to the smaller size of the alkyl groups, 
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which are not able to effectively interact with Ile123 in the pjDHFR active site. The N9-butyl 
analog 22 demonstrated the best potency for pjDHFR of the series which could be attributed 
to the length of the butyl substitution which can interact with Ile123 (pjDHFR) better than 
the smaller alkyl groups of 18–21. Compound 22 with the best potency (IC50, 66 nM) 
against pjDHFR demonstrated a 14-fold selectivity for pjDHFR, whereas 15 despite a 
comparatively lower potency for pjDHFR (IC50, 80 nM) showed a significantly higher 
selectivity. Thus, in the N9-substituted pyrido[3,2-d]pyrimidine-2,4,6-triamine series, 15 
remained the best in terms of its potency and selectivity for pjDHFR. Though the 
selectivities of some of these compounds fall short of that for TMP for pjDHFR, the potency 
is equivalent or slightly better than TMP. Utilizing the information provided by this study, 
the design and synthesis of potentially more potent and selective compounds are currently 
underway and will be the subject of future reports.
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Agents that have been used to treat PCP
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(A) Docked pose of 1 (magenta) in the homology model of pjDHFR and (B) Docked pose of 
1 (magenta) in the crystal structure of hDHFR (PDB: 4QJC, 1.62 Å)[30]
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(A) Superimposition of docked pose of 1 (magenta) and 9 (cyan) in the homology model of 
pjDHFR and (B) Docked pose of 1 (magenta) and 9 (cyan) in the crystal structure of hDHFR 
(PDB: 4QJC, 1.62 Å)[30]
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(A) Superimposition of docked pose of 9 (cyan) and 18 (magenta) in the homology model of 
pjDHFR and (B) Docked pose of 9 (cyan) and 18 (magenta) in the crystal structure of 
hDHFR (PDB: 4QJC, 1.62 Å)[30]
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Synthesis of intermediate 26
a) 0% HNO3, H2SO4, reflux, 3 h; b) CuCN, 180 °C, 15 min; c) aniline, monoethyl glycol, 
pyridine, 140 °C, 12 h; d) aniline, LDA, THF, −78 °C, 12 h
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Synthesis of target compounds 9–22
a) substituted aniline, isopropanol, 130 °C, 3–16 h; b) conc. HCl, Fe powder, reflux, 0.5–2 h; 
c) chlorformamidine HCl, dimethyl sulfone, 140 °C, 3–16 h
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Table 1.
Inhibitory Concentrations (IC50, in nM) against Recombinant DHFR from pjDHFR and human DHFR 
(hDHFR) and Selectivity Ratios[28]
R1 R2 pjDHFR (IC50, in nM) hDHFR (IC50, in nM) Selectivity Ratio [hDHFR/pjDHFR]
1 H H 300 190 <1
2 H 4-CH3 620 2100 3
3 H 4-OCH3 400 3650 9
4 H 2′,3′-(CH)4 250 2100 8
5 H 3′,4′-(CH)4 400 2200 5
6 H 3′,4′,5′ -triF 870 3100 4
TMP 120 32200 268
PTX 1.6 3.0 2
TMQ 2.1 2.6 1
These assays were carried out at 37 °C under 18 μM dihydrofolic acid concentration. The standard error of the means for these values is 12% or 
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Table 2.
Inhibition Concentrations (IC50) against pcDHFR and rlDHFR [33, 34]
# X Y pcDHFR (nM) rlDHFR (nM)
7 N C 1400 430
8 C N 6100 500
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Table 3.
Inhibition Concentrations (IC50) of 9–22 against pjDHFR and hDHFR and Selectivity Ratios
# R1 R2 pjDHFR (IC50, in nM) hDHFR (IC50, in nM) Selectivity Ratio [hDHFR/pjDHFR]
9 H H 122 1526 13
10 H 4′-CH3 174 2626 15
11 H 4′-OCH3 239 2459 10
12 H 4′-OH 150 1576 10
13 H 2′,3′-(CH)4 112 1098 10
14 H 3′,4′-(CH)4 275 3185 12
15 H 3′,4′,5′-triF 80 2253 28
16 H 3′,4′-diF 155 1808 12
17 H 4′-OCF3 194 4125 21
18 CH3 H 96 942 10
29 CH2CH3 H 150 1571 10
20 CH2CH2CH3 H 123 1338 11
21 CH(CH3)2 H 201 1373 7
22 CH2CH2CH2CH3 H 66 903 14
TMP
b 92 24500 266
PTX
c 41 2 0.05
a
These assays were carried out at 37 °C under 9 μM dihydrofolic acid concentration. The standard error of the means for these values is 12% or 
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